Acadia Pharmaceuticals (ACAD) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Q3 2025 value amounting to -$79.5 million.
- Acadia Pharmaceuticals' Other Gross PP&E Adjustments fell 913.46% to -$79.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.5 million, marking a year-over-year decrease of 913.46%. This contributed to the annual value of -$59.6 million for FY2024, which is 3284.79% up from last year.
- Per Acadia Pharmaceuticals' latest filing, its Other Gross PP&E Adjustments stood at -$79.5 million for Q3 2025, which was down 913.46% from -$81.0 million recorded in Q2 2025.
- Acadia Pharmaceuticals' 5-year Other Gross PP&E Adjustments high stood at -$59.6 million for Q4 2024, and its period low was -$95.2 million during Q4 2021.
- In the last 5 years, Acadia Pharmaceuticals' Other Gross PP&E Adjustments had a median value of -$75.8 million in 2025 and averaged -$75.4 million.
- As far as peak fluctuations go, Acadia Pharmaceuticals' Other Gross PP&E Adjustments crashed by 18126.66% in 2021, and later surged by 3284.79% in 2024.
- Acadia Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at -$95.2 million in 2021, then increased by 2.2% to -$93.1 million in 2022, then rose by 4.73% to -$88.7 million in 2023, then soared by 32.85% to -$59.6 million in 2024, then plummeted by 33.42% to -$79.5 million in 2025.
- Its Other Gross PP&E Adjustments stands at -$79.5 million for Q3 2025, versus -$81.0 million for Q2 2025 and -$75.8 million for Q1 2025.